June 03, 2014

Transfer of Assets

On 3 June 2014, the Board of Directors of Samsung Electronics approved the transfer of assets (biopharmaceutical technology) to Samsung Biologics Co., Ltd., an affiliated company of Samsung Electronics. Samsung Biologics is a global company manufacturing and research and development of biopharmaceutical products. The company is committed to quality-driven manufacturing of biopharmaceutical products and supports both collaborative novel drug development and high-quality, fast-turnaround contract manufacturing partnerships.

▫ Details

1. Date of Transfer (scheduled): 5 June 2014

2. Items of Transfer: Biopharmaceutical technology

3. Value of Transfer: KRW 10,433,000,000
* The value of transferrable asset was determined by an external auditor.
The currency rate of 1,024.3 KRW/Dollar (FX rate on 4 June 2014) was used
to determine the value.

4. Attendance of Independent Director at the BoD meeting: 5 (100%)

5. Attendance of Audit Committee members at the BoD meeting: Yes (100%)

Welcome to Samsung

Sign up & get 10% off

Sign up and get 10% off your first order of $100 or more! Shop Samsung.com to find the best tech at the best prices and recieve news on our latest technology and exclusive offers.*

*Exclusion apply. Order must be a minimumm of $100 or more. Offer valid only for new Samsung.com customers. Must sign up for emails by 11/12/16. Promo code must be used by 11/19.

Fast, easy checkout with Shop Samsung App
Easy sign-in, Samsung Pay, notifications, and more!
Or continue shopping on Samsung.com
The Shop Samsung app
Free standard shipping, exclusive offers and financing options.
The Shop Samsung app
Free standard shipping, exclusive offers and financing options.

You Are About To Be Redirected To Investor Relations Information for U.S.

Thank you for visiting Samsung U.S. Investor Relations. You will be redirected via a new browser window to the Samsung Global website for U.S. investor relations information.